Clinical Trial

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Trial Details
NCT Number NCT07265466
Lead Sponsor Onconic Therapeutics Inc.
Conditions Drug Drug Interaction (DDI)
Enrollment 96 participants
Start Date 2025-11-17
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-04